Altruist Biologics is set to redefine the landscape of biologics development with the introduction of Altru-CON, a groundbreaking high-concentration formulation technology platform. This innovative system aims to streamline the development and commercialization of high-dose biologics, accommodating protein concentrations of up to 200 mg/mL while achieving significant viscosity reductions.
Navigating Industry Trends
As the biologics sector shifts towards higher drug concentrations and more convenient delivery methods, Altru-CON stands at the forefront of this evolution. By offering dual advancements in concentration and stability, the platform caters to the growing demand for patient-friendly therapeutics. Its design incorporates a high-throughput screening process alongside an intelligent excipient optimization system, utilizing over 30 excipient combinations to create stable formulations between 100 and 200 mg/mL.
Overcoming Technical Challenges
Developing high-concentration biologics presents several technical challenges, including managing protein interactions, controlling viscosity, and ensuring long-term stability. Altru-CON addresses these issues effectively. The enhanced concentration not only increases flexibility in injection volumes but also reduces dosing frequency, simplifying cold chain logistics. This efficiency contributes to improved manufacturing processes, streamlining the path to Investigational New Drug (IND) submission.
Advanced Screening Techniques
Altruist’s commitment to innovation is evident in its use of high-throughput screening for more than 40 buffer systems. This approach allows for accurate predictions of viscosity and aggregation risks, significantly enhancing candidate selection. By proactively addressing potential reformulation needs during late-stage development, Altruist boosts the overall probability of success for its clients.
Proven Track Record
To date, Altruist has successfully supported the development of one approved high-concentration product, alongside two late-stage clinical programs and six early-stage clinical trials, as well as ten preclinical projects. This robust portfolio underscores the effectiveness of the Altru-CON platform and its capacity to meet the demands of modern biologics development.
Leadership Vision
Dr. Kaisong Zhou, Chairman and CEO of Altruist Biologics, expressed his enthusiasm for the new platform, stating, “Altru-CON represents a strategic expansion of our high-concentration formulation capabilities, supporting next-generation biologics from low to ultra-high concentrations with improved stability and viscosity control.” This commitment to client-centric service and advanced formulation technology is central to Altruist’s mission of delivering innovative therapies to patients.
A Commitment to Quality
Altruist Biologics prides itself on being a reliable partner in the contract development and manufacturing organization (CDMO) space. As a wholly owned subsidiary of Innovent Biologics, the company focuses on the development and manufacturing of a range of biologics, including antibodies and fusion proteins. Altruist operates state-of-the-art, CGMP-compliant facilities that meet global regulatory standards, ensuring high-quality biopharmaceuticals are available to patients worldwide.
Future Prospects
With a total capacity of 60KL at its Suzhou site and plans for further expansion in Hangzhou, Altruist is poised for significant growth. The Hangzhou facility, featuring the first and largest 20,000-liter bioreactors in China, will ultimately hold a total capacity of 172KL. This infrastructure positions Altruist to enhance its service offerings and meet evolving market demands.
Takeaways
- Altru-CON enables high concentrations of biologics, enhancing patient delivery options.
- The platform uses advanced screening to mitigate viscosity and aggregation risks.
- Altruist has a proven track record in supporting high-concentration product development.
In a world where the demand for biologics is ever-increasing, Altruist Biologics’ Altru-CON platform represents a significant leap forward. By addressing both the technical challenges and the evolving needs of the healthcare landscape, Altruist is not just keeping pace with industry trends but is actively shaping the future of biologics. Their commitment to innovation and quality ensures that advanced therapies can reach patients more efficiently and reliably than ever before.
Read more → www.finanznachrichten.de